Albinism Clinical Trial
Official title:
Clinical Trial to Evaluate Levodopa as Treatment to Improve Vision in Individuals With Albinism
This project will evaluate the effect of two doses of levodopa (L-DOPA) in a randomized, placebo-controlled, double-masked clinical trial to see if vision can be improved in individuals with albinism. The hypothesis is that providing L-DOPA to the retinas of these individuals may increase melanin pigment production. Increased melanin has previously been shown to be associated with improved vision.
A group of 45 individuals with the clinical findings of oculocutaneous albinism (OCA) will be randomly assigned to one of 3 treatment groups: treatment with 0.76 mg/kg/d with 25% carbidopa, 0.51 mg/kg/d levodopa with 25% carbidopa [divided into 3 doses/d), or placebo. Subjects will be between ages 3 and 60 years. Blood will be drawn to determine the mutation(s) in the genes that causes OCA. Primary outcome will be binocular best-corrected visual acuity measured with the EVA. Enrollment and 20 week examination will be complete eye exam with fundus photos. At weeks 5, 10, and 15, exams will include just vital signs and BCVA. At all visits, a review of potential side effects will be conducted. Between visits, subjects will be contacted to determine if any side effects have occurred. The study will remain double masked until the last study examination on the last subject has been performed. At that time, the data will be statistically analyzed and subjects will be informed re: treatment assignment, mutations found, and the study results. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001596 -
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
|
Phase 2 | |
Terminated |
NCT01663935 -
Vision Response to Dopamine Replacement
|
Phase 2 | |
Recruiting |
NCT04281732 -
Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision
|
||
Recruiting |
NCT05954416 -
FARD (RaDiCo Cohort) (RaDiCo-FARD)
|
||
Completed |
NCT00001153 -
Visual Function and Ocular Pigmentation in Albinism
|
N/A | |
Recruiting |
NCT05696912 -
Functional Tests to Resolve Unsolved Rare Diseases. Rares.
|
N/A | |
Recruiting |
NCT06330350 -
Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
|
||
Enrolling by invitation |
NCT06330324 -
Reproductive Options in Inherited Skin Diseases
|
||
Completed |
NCT04658381 -
Genetic Analysis and Multimodal Retinal Imaging of Asymptomatic Fovea Plana Cases in the General Population
|
N/A | |
Completed |
NCT01838655 -
Nitisinone for Type 1B Oculocutaneous Albinism
|
Phase 1/Phase 2 |